Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| (NASDAQ: RVMD) | Delayed: 187.69 -6.59 (3.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $194.28 | 52 Week High | $ | |||
| Open | $192.06 | 52 Week Low | $ | |||
| Day High | $194.59 | P/E | N/A | |||
| Day Low | $185.34 | EPS | $ | |||
| Volume | 1,487,200 | |||||
